CD226 and dermatomyositis: Both in patients with DM (n = 10) (Fig. 2b) and HCs (n = 5) (Fig. 2c), the percentage of proliferating cells was the highest in the TIGIT–CD226+ subset, followed by the TIGIT+CD226+, TIGIT+CD226−, and TIGIT−CD226− subsets.